Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOSTON-2: L-CsA for BOS in Double Lung Transplant Recipients
NCT03656926Phase 3Completed
- Sponsor
- Zambon
- Start
- Mar 2019
- Primary completion
- Mar 2024
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial in Bronchiolitis Obliterans Syndrome (BOS) comparing L-CsA treatment plus SoC with Standard of Care (2 arms). Primary endpoint: Forced Expiratory Volume in 1 second at 48 weeks. Started Mar 2019; status: completed.
02
Drugs
liposomal cyclosporine A
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on NCT03656926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656926.